Progress in Neuro-psychopharmacology and Biological Psychiatry
July 1, 2026
Guilherme Lodetti, Rafael Mariano de Bitencourt, Antonio Inserra et al.
BackgroundAlcohol use disorder (AUD) remains difficult to treat with lasting success, leading to growing interest in alternative therapeutic approaches. Psychedelic compounds such as Ayahuasca, a traditional brew used in Indigenous Amazonian ceremonies containing N,N-dimethyltryptamine (DMT) along with monoamine oxidase-inhibiting β-carbolines, have shown promise in reducing addictive...
Psychopharmacology
April 14, 2026
Guilherme Lodetti, Antonio Inserra, Henrique Redivo et al.
BACKGROUND: Chronic stress is a risk factor for the development of anxiety, depression, and comorbid systemic conditions. Ayahuasca (AYA) has been used for hundreds of years and it elicits antidepressant and anxiolytic effects. However, it remains unknown whether AYA elicits a behavioral and biochemical protective effect in chronic stress. AIM OF THE STUDY: Therefore, we evaluated the...
Behavioural Brain Research
May 8, 2025
Larissa da Silva Joaquim, Lara Rodrigues da Rosa, Yasmin Strickert et al.
5 citations
Ischemic stroke is a leading cause of death and disability worldwide. Survivors face disability and psychiatric sequelae resulting from ischemia-induced cell death and associated neuroinflammation, and oxidative stress. Herbal medicines have been shown to elicit neuroprotective effects following stroke due to their anti-inflammatory and antioxidant effects. Preliminary evidence suggests that...
Molecular Neurobiology
May 1, 2025
Rick Wilhiam de Camargo, Larissa Joaquim, Richard Simon Machado et al.
13 citations
The psychoactive decoction Ayahuasca (AYA) used for therapeutic and religious purposes by indigenous groups and peoples from Amazonian regions produces anti-inflammatory and neuroprotective effects. Thus, it may be useful to attenuate the neuroinflammation and related anxiety- and depressive-like symptoms elicited by inflammatory insults such as sepsis. Rats were pretreated for 3 days with...
Schizophrenia Research
April 1, 2025
Sofia de Almeida Queiroz, Linério Ribeiro de Novais Junior, Anita Beatriz Pacheco de Carvalho et al.
2 citations
Schizophrenia (SCZ) has limited treatment options, often with significant side effects. Cannabidiol (CBD), a non-euphoric phytocannabinoid, has shown potential as a novel therapeutic option in SCZ due to antipsychotic-like, anti-inflammatory, and antioxidant properties. We compared the therapeutic effects of CBD and risperidone (RISP) in a rat model of SCZ induced by sub-chronic ketamine (KET),...
Progress in neuro-psychopharmacology & biological psychiatry
December 20, 2024
Guilherme Lodetti, Rafael Mariano de Bitencourt, Eduardo Pacheco Rico
9 citations
Alcohol is a harmful drug, and reducing its consumption is a significant challenge for users. Furthermore, alcohol dependence is often treatment-resistant, and no completely effective treatment model is available for chemical dependence. Classic psychedelics, such as LSD, psilocybin, and ayahuasca have been used in different clinical and pre-clinical trials, demonstrating promising...
Revista Neurociências
October 16, 2024
Vitória Pereira de Menezes, Luis Felipe Batista, Vicente Meneguzzo et al.
Introdução. Os transtornos mentais apresentam alta incidência na população, mas as opções terapêuticas são limitadas por efeitos colaterais e baixa eficácia. Nesse cenário, a Ayahuasca, utilizada por povos indígenas há milênios, surge como alternativa para tratar condições como ansiedade e depressão. Objetivo. Avaliar as mudanças psicológicas em participantes iniciantes de cerimônias com...
Behavioural Brain Research
July 14, 2022
Marina Goulart Da Silva, Guilherme Cabreira Daros, Fabiana Pereira Santos et al.
22 citations
The objective of this study was to evaluate the behavioral response of ayahuasca in rats submitted to neuroinflammation through the intraperitoneal application of lipopolysaccharide (0.63 mg/kg/mL). Eighty animals, male, about 90 days old, were divided into control and LPS groups and later into prevention and treatment subgroups. The prevention subgroup was administered ayahuasca or saline...
Behavioural Brain Research
November 6, 2020
Marina Goulart Da Silva, Guilherme Cabreira Daros, Rafael Mariano de Bitencourt
21 citations
Ayahuasca is a decoction with psychoactive properties, used for millennia for therapeutic and religious purposes by indigenous groups and the population of amazonian countries. As described in this narrative review, it is essentially constituted by β-carbolines and tryptamines, and it has therapeutic effects on behavioral disorders due to the inhibition of the monoamine oxidase enzyme and the...